Shenogen Pharma Group Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety coupled to an estrogen receptor α (ER-α; ESR1)-targeting moiety through a linker reported to be useful for the treatment of cancer, infections, immunological disorders, diabetes, inflammatory and cardiovascular disorders.
Acerand Therapeutics (Hong Kong) Ltd. has synthesized compounds acting as EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer.
S-Infinity Pharmaceuticals Co. Ltd. has disclosed azaquinoline ring-containing compounds acting as Tpl-2/Cot (MAP3K8) kinase inhibitors reported to be useful for the treatment of cancer, diabetes and inflammatory disorders.
Ubiquitin-specific proteases (USPs) play a crucial role in tumor progression, regulating the stability or functions of specific substrate proteins. USP33 expression is altered in several types of cancer, including ovarian cancer, pancreatic cancer and glioma.
Sigma-2 receptor modulation using exogenous ligands reduces cellular damage associated with central nervous system degeneration in age-related pathologies such as Alzheimer’s disease, Parkinson’s disease or dry age-related macular degeneration. Researchers from Cognition Therapeutics Inc. described the neuroprotective effect of CT-2074, a sigma-2 receptor in preclinical models of open-angle glaucoma.
A recent study by researchers from Fudan University and Tau Cambridge Ltd. explored a novel therapeutic strategy that combines targeting CD47 with ANGPTL3, a key regulator of lipid metabolism, as a potential treatment for atherosclerosis.
Atavistik Bio Inc. has entered into a research collaboration with Pfizer Inc. to accelerate the discovery of novel precision allosteric therapeutics for unmet medical needs. Under the collaboration, Atavistik Bio will leverage its proprietary AMPS platform to identify novel allosteric binders against two undisclosed targets selected by Pfizer.
RSS
